



Long-Term Impact of the COVID-19 Pandemic On In-Hospital Antibiotic Consumption and Antibiotic Resistance

Guest Editors:

Dr. Maria Musso

Respiratory Infectious Diseases
Unit, National Institute for
Infectious Diseases “L.
Spallanzani” IRCCS, 00149 Rome,
Italy

Dr. Gina Gualano

Respiratory Infectious Diseases
Unit, National Institute for
Infectious Diseases “L.
Spallanzani” IRCCS, 00149 Rome,
Italy

Deadline for manuscript
submissions:

closed (15 September 2023)

Message from the Guest Editors

The global threat of antimicrobial-resistant infection has become worse in recent years.

During the first year of the pandemic, more than 29,400 people died from antimicrobial-resistant infections associated with healthcare. Of these, nearly 40% of cases obtained the infection while they were in the hospital.

This Special Issue focuses on the long-term impact of the COVID-19 pandemic on in-hospital antibiotic consumption and antibiotic resistance.

We are interested in following areas:

1. Tracking antimicrobial resistance, including detection and reporting data regarding both the assessment of antimicrobial-resistant germ burden and antibiotic and antifungal use during the COVID-19 pandemic;
2. Pandemic-related changes to infection prevention and control practices;
3. Development of novel antimicrobial stewardship initiatives during the COVID-19 pandemic;
4. Development of differentiated antimicrobial stewardship initiatives in different wards and settings;
5. Development of antimicrobial stewardship initiatives for specific microorganisms or conditions (e.g., UTI, RTI);
6. Evaluation of the impact of new antimicrobial stewardship initiatives on patient outcomes).





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)